Search Results for “mental health” – Page 20 – media

The mechanism by which G protein mutations lead to excessive activation of T cells through non classical pathways

Writing | Snow Moon G protein coupled receptors (GPCRs) guide cellular responses to environmental signals, including hormones, neurotransmitters, and chemokines. This process is achieved through a complex biochemical cycle mediated by heterotrimeric G protein. After GPCR binds to the ligand, the G α subunit binds to GTP, becomes active, and separates from the G β – γ complex and GPCR. The separated G α – guanosine triphosphate (GTP) and free G β – γ initiate downstream signaling, including the generation of second messengers, biochemical interactions, and ion channel changes. The GTPase activity of G α hydrolyzes GTP to guanosine diphosphate (GDP), thereby terminating signal transduction and allowing Gabg to reassemble with GPCRs, enabling cells to respond to reactivation of GPCRs. In the G α protein family, the Gai/o family includes inhibitory subtypes that regulate biological responses by inhibiting the production of cyclic adenosine monophosphate (cAMP) by adenyl cyclase AC. AC ...
- Source: drugdu
- 75
- October 23, 2024
Yuyue Medical’s “wishful thinking”

The performance of the leading player ResMed fully reflects this point. In fiscal year 2024, ResMed’s equipment revenue alone reached US$2.444 billion. As another example of the “razor + blade” model, the revenue brought by home ventilators is not limited to equipment. In fiscal year 2024, in addition to equipment, ResMed’s consumables revenue reached US$1.657 billion, a year-on-year increase of 14%, which is much higher than the equipment; and ResMed also opened up the space for the SAAS business model, with revenue reaching US$584 million, a year-on-year increase of 17%. Under the three-wheel drive model of equipment, consumables, and software, ResMed’s total revenue in fiscal year 2024 reached US$4.685 billion and its net profit reached US$1.021 billion. In the huge medical equipment industry, such a scale is not considered the top, but it must not be ignored in the subdivided field. The outstanding performance of the leader naturally attracted the ...
- Source: drugdu
- 54
- October 23, 2024
Huawei enters the hot track of medical devices

Recently, the website of the State Intellectual Property Office updated a new invention patent, named “Method for controlling stimulator, stimulator, brain-computer interface system and chip”, and the inventor of the patent is Huawei Technologies Co., Ltd. It is reported that this is Huawei’s second brain-computer interface related patent. As early as June 2023, Huawei announced a patent called “A brain-computer interface device and information acquisition method”. Brain-computer interface is one of the most popular phenomenal technologies in recent years, and its potential in the medical field is highly expected by the industry. According to McKinsey’s calculations, the potential market size of global brain-computer interface medical applications is expected to reach US$40 billion in 2030, and it is expected to exceed the US$145 billion mark by 2040. With the increase in R&D investment, the medical application of brain-computer interface has gradually shifted from early abstract concepts to landing results. In September, ...
- Source: drugdu
- 72
- October 21, 2024
Suda Testing participates in the release of ESG standards for medical device companies, promoting sustainable development in the industry

On the morning of October 14, sponsored by the “the Belt and Road” Life Science and Technology Promotion Alliance, and jointly organized by the Shenzhen Life Science and Technology Industry University Research Capital Alliance, Suzhou Suda Health and Environmental Technology Research Institute Co., Ltd., Shenzhen Huada Intelligent Manufacturing Technology Co., Ltd., and Jiewen (Shenzhen) Technology Services Co., Ltd., the ESG standard seminar for the medical device industry was successfully held in Shenzhen. The purpose of this seminar is to jointly explore the current situation and challenges of ESG standards in the medical device industry, promote the formulation and implementation of standards, and enhance the industry’s international competitiveness and sustainable development capabilities. At the beginning of the meeting, relevant leaders from the Standards Department of Shenzhen Municipal Market Supervision Administration, Suzhou Medical Device Industry Development Group Co., Ltd., the “the Belt and Road” Life Technology Promotion Alliance, and Suzhou Suda Health ...
- Source: drugdu
- 75
- October 19, 2024
Bankruptcy and divestment, breathing giant achieves rebirth

Recently, Zoll announced that it has completed the previously announced acquisition of some assets of Vyaire Medical’s ventilator business. In August of this year, these two companies announced this transaction after Vyaire initiated Chapter 11 bankruptcy proceedings. Now that the dust has settled on the acquisition, Zoll will launch Vyaire’s Bellavista, Fabian, LTV, and 3100 HFOV series of ventilators, further expanding its respiratory care product line. It is worth mentioning that Vyaire was an important force in the supply of ventilators during the early stages of the COVID-19 pandemic, but applied for bankruptcy protection due to operational difficulties. And Medtronic also chose to withdraw due to the fact that its ventilator business is no longer profitable. Zoll’s acquisition undoubtedly brings new vitality and hope to the market. 01. The rise and fall of rising stars in ventilators Zoll stated that the acquired product line of ventilators and their related consumables, ...
- Source: drugdu
- 75
- October 18, 2024
Another “hundred-ton” synthetic biology production line was successfully delivered, 60 million yuan!

On September 23, the food additive synthetic biology production line project of the biotechnology company undertaken by Sanxi Group successfully completed all installation and commissioning work and was delivered on schedule, which marked that the project has fully entered the production and operation stage. It is reported that the total investment of the production line is about 60 million yuan, and it is equipped with 4 fully automatic precision fermentation production lines. These production lines are equipped with advanced automated separation and purification systems, which can monitor various key parameters in the production process in real time to ensure comprehensive, efficient and precise control of product quality. The successful delivery of this project not only demonstrates Sanxi Group’s deep technical accumulation in the field of synthetic biology equipment manufacturing, but also reflects its efficient project management and delivery capabilities. In recent years, with the continuous development of technologies such as ...
- Source: drugdu
- 61
- October 17, 2024
Important document! Secondary bargaining is “stopped”

Regarding the scope of the special rectification of “secondary bargaining” defined in the notice, the author consulted the relevant responsible personnel of the Finance Department of the Hunan Provincial Health Commission, and received the reply: This “secondary bargaining” rectification focuses on the behavior of public hospitals not settling according to the agreed purchase and sale prices in order to obtain irregular rebates. At present, most hospitals in Hunan Province are involved in “secondary bargaining” rebates to varying degrees and in different forms, such as bearing the cost of drug consumption fund recovery and deducting penalties for excessive drug use as the name and method of rebates. The rebate income from “secondary bargaining” is used by hospitals to supplement related operating costs. This time, the Hunan Provincial Health and Health System carried out a special rectification work on “secondary bargaining” of drug consumption, requiring it to be completed in October. In ...
- Source: drugdu
- 79
- October 16, 2024
Sanxi Group’s Synthetic Biology Production Line is Delivered as Scheduled

It is reported that the total investment of the production line is about 60 million yuan, and it is equipped with four fully automatic precision fermentation production lines. These production lines are all equipped with advanced automated separation and purification systems, which can monitor various key parameters in the production process in real time, ensuring comprehensive, efficient, and precise control of product quality. The successful delivery of this project not only demonstrates Sanxi Group’s profound technical accumulation in the field of synthetic biological equipment manufacturing, but also demonstrates its efficient project management and delivery capabilities. In recent years, with the continuous development of technologies such as gene editing and artificial intelligence, synthetic biology has sparked a new wave of research. Scientists have high hopes for this cutting-edge science, hoping to use this technology to improve human health, address food crises, alleviate global warming and other common problems faced by humanity. ...
- Source: drugdu
- 63
- October 15, 2024
A major pharmaceutical province issued a document to dig deep into medical corruption

In May this year, the National Health Commission and 14 other departments issued the “Notice on Printing and Distributing the Key Points for Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sale and Medical Services in 2024”, which includes 5 parts and 15 items. The local level has also successively issued the key points for correcting unhealthy trends in 2024. Judging from the above-mentioned “Notice” issued by Shanghai, the key points for Shanghai’s corrective work in 2024 are basically consistent with the national documents, and some new content has also been added, totaling 5 parts and 18 items. The “Notice” clearly states that the city’s centralized rectification of corruption in the pharmaceutical field and the centralized rectification of unhealthy trends and corruption around the masses should be carried out in a coordinated manner, and the construction of systems in the field of pharmaceutical purchase and sale should be ...
- Source: drugdu
- 88
- October 12, 2024
【EXPERT Q&A】Can metformin fight aging?

Drugdu.com expert’s response: Metformin, a widely used antidiabetic drug, has shown potential in recent research on anti-aging. Specifically, its anti-aging effects are manifested in the following aspects: Ⅰ. Scientific Research Achievements Research by the Chinese Academy of Sciences Team: After an extensive 8-year study, the team led by Liu Guanghui from the Institute of Zoology, Chinese Academy of Sciences, discovered that metformin can reset the intrinsic program of cellular aging, significantly delaying aging in primates. This achievement was published in the journal “Cell”, providing new insights into the biological mechanisms of aging and potential strategies for future interventions in human aging. Experimental Evidence: The research team conducted a 40-month follow-up study on middle-aged and elderly male crab-eating macaques. The results showed that individuals who took metformin long-term exhibited significant delays in aging, including reduced brain cortex atrophy, improved cognitive function, delayed periodontal bone degeneration, and protection of multiple tissues and ...
- Source: drugdu
- 71
- October 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.